Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy.
Pedro Luiz Serrano UsÓn JuniorJairo WagnerMarcus Vinicius de Nigro CorpaIracema Moraes CoelhoRobert A NagourneyNise Hitomi YamaguchiPublished in: SAGE open medical case reports (2019)
The clinical management of patients with carcinoma of unknown primary continues to present a considerable challenge for practicing oncologists. Laboratory platforms capable of examining cellular response to injury, growth factor withdrawal, and cytotoxic insult at the level of cellular function may provide insights for drug selection in this patient population.